title: Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression.
abstract: Primary biliary cirrhosis (PBC) is a chronic, progressive, cholestatic liver disease. Interleukin-1 beta (IL-1 beta) may play a role in the pathogenesis of PBC by contributing to altered immune function and fibrosis. Colchicine or methotrexate has some beneficial effects in the treatment of PBC, and also affects interleukin-1 (IL-1). Therefore, we prospectively studied the synthesis of IL-1 beta by peripheral blood mononuclear cells (PBMC) from 42 patients with PBC entered into a randomized, double-blind, double-dummy controlled trial of colchicine and methotrexate. PBMC obtained at entry, 6, 12, 18, and 24 months were stimulated to produce IL-1 beta with phytohemagglutinin (PHA), lipopolysaccharide (LPS), Staphylococcus epidermidis, recombinant IL-2, or mitochondrial antigen. Patients in the two treatment groups did not differ at entry in biochemical measures or liver histological stage. Over 24 months in both groups, serum bilirubin and histologic stage remained stable and alkaline phosphatase decreased significantly. For all patients, synthesis of IL-1 beta increased constitutively and in response to immune-mediated stimulants (PHA, IL-2, and mitochondrial antigen) but not the bacterial stimulants LPS or S epidermidis. Compared with levels of IL-1 beta at entry, PHA induced increases for patients treated with methotrexate (12, 18, and 24 months) or colchicine (18 and 24 months). At 24 months, IL-2-induced IL-1 beta synthesis was increased in patients treated with methotrexate, whereas S epidermidis-induced IL-1 beta was enhanced in colchicine-treated patients. Before treatment, IL-1 beta production did not relate to severity of disease except in response to S epidermidis.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatrics, New England Medical Center, Boston, MA 02111, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Miller
authors.forename: A
authors.initials: A
authors.lastname: Sharma
authors.forename: A F
authors.initials: AF
authors.lastname: McKusick
authors.forename: J P
authors.initials: JP
authors.lastname: Tassoni
authors.forename: C A
authors.initials: CA
authors.lastname: Dinarello
authors.forename: M M
authors.initials: MM
authors.lastname: Kaplan
mesh_terms: D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D003078:Colchicine / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008099:Liver / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D013212:Staphylococcus epidermidis
chemical_list: D007375:Interleukin-1; D000469:Alkaline Phosphatase; D001663:Bilirubin; D003078:Colchicine; D008727:Methotrexate